Inventor · disambiguated record
Terri Sebree
Also filed as: SEBREE TERRI · SEBREE TERRI B
25 granted patents·31 pending applications·141 citations·filing 2007–2025
96Inventor score
Files withZYNERBA PHARMACEUTICALS INC21HARMONY BIOSCIENCES MAN INC12NUPATHE INC7SEBREE TERRI B6TEVA PHARMACEUTICALS INT GMBH6
Top patents by PatentIndex Score
56 records- 0195US11458110B2Treatment of Fragile X Syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2020·Granted Oct 4, 2022·4 cites·7 claims
- 0295US10758497B2Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Sep 1, 2020·14 cites·7 claims
- 0394US11779549B2Treatment of Fragile X Syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Granted Oct 10, 2023·2 cites·2 claims
- 0494US10568848B2Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Feb 25, 2020·13 cites·8 claims
- 0594US10471022B2Treatment of fragile X syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Nov 12, 2019·14 cites·6 claims
- 0694US10314792B2Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2018·Granted Jun 11, 2019·13 cites·7 claims
- 0794US10213390B1Treatment of fragile X syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2018·Granted Feb 26, 2019·19 cites·8 claims
- 0893US11458109B2Treatment of 22Q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2019·Granted Oct 4, 2022·7 cites·15 claims
- 0992US12226373B2Treatment of fragile X syndrome with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2023·Granted Feb 18, 2025·1 cites·8 claims
- 1092US12213951B2Treatment of autism with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2023·Granted Feb 4, 2025·1 cites·8 claims
- 1192US8470853B2Transdermal methods and systems for the delivery of anti-migraine compoundsANDERSON CARTER R·Filed 2011·Granted Jun 25, 2013·7 cites·14 claims
- 1291US8366600B2Polyamine enhanced formulations for triptan compound iontophoresisNUPATHE INC·Filed 2008·Granted Feb 5, 2013·9 cites·27 claims
- 1390US12186282B2Treatment of 22Q11.2 deletion syndrome with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2022·Granted Jan 7, 2025·1 cites·20 claims
- 1490US7973058B2Transdermal methods and systems for the delivery of anti-migraine compoundsNUPATHE INC·Filed 2008·Granted Jul 5, 2011·13 cites·13 claims
- 1584US8475829B2Implants for the treatment of dopamine associated statesSEBREE TERRI B·Filed 2007·Granted Jul 2, 2013·5 cites·34 claims
- 1682US2025213465A1Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1782US2025339450A1Treatment of syngap1 encephalopathyHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 1881US9272137B2Transdermal methods and systems for the delivery of anti-migraine compoundsANDERSON CARTER R·Filed 2011·Granted Mar 1, 2016·13 cites·15 claims
- 1979US8475830B2Implants for the treatment of dopamine associated statesSEBREE TERRI B·Filed 2008·Granted Jul 2, 2013·2 cites·16 claims
- 2079US2022096396A1Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2179US2025205174A1Treatment of 22q11.2 deletion syndrome with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2024·Application pending·0 cites
- 2277US12508270B2Treatment of behavioral impairment in developmental and epileptic encephalopathyHARMONY BIOSCIENCES MAN INC·Filed 2022·Granted Dec 30, 2025·0 cites·14 claims
- 2377US2024122873A1Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2474US2025134832A1Treatment of autism with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 2574US2025134833A1Treatment of fragile x syndrome with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 2674US2025195451A1Treatment of syngap1 encephalopathyHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 2773US2025288539A1Treatment of fragile x syndrome and autism spectrum disorder with cannabidiolHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 2872US8155737B2Pharmacokinetics of iontophoretic sumatriptan administrationSEBREE TERRI B·Filed 2008·Granted Apr 10, 2012·1 cites·22 claims
- 2972US2020214995A1Treatment of autism with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3070US8597272B2Pharmacokinetics of iontophoretic sumatriptan administrationSEBREE TERRI B·Filed 2012·Granted Dec 3, 2013·1 cites·21 claims
- 3169US2021077421A1Treatment of syngap1 encephalopathyZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3269US2025302734A1Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adultsHARMONY BIOSCIENCES MAN INC·Filed 2025·Application pending·0 cites
- 3368US2021401769A1Treatment of fragile x syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3467US8845612B2Methods for iontophoretically treating nausea and migraineSEBREE TERRI B·Filed 2010·Granted Sep 30, 2014·1 cites·18 claims
- 3567US2019083388A1Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3666US2021030665A1Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adultsZYNERBA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3765US10278916B2Implants for the treatment of dopamine associated statesNUPATHE INC·Filed 2014·Granted May 7, 2019·0 cites·12 claims
- 3865US2021369643A1Treatment of fragile x syndrome and autism spectrum disorder with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3963US9427578B2Pharmacokinetics of iontophoretic sumatriptan administrationTEVA PHARMACEUTICALS INT GMBH·Filed 2014·Granted Aug 30, 2016·0 cites·13 claims
- 4063US2016317464A1Transdermal methods and systems for the delivery of anti-migraine compoundsTEVA PHARMACEUTICALS INT GMBH·Filed 2016·Application pending·0 cites
- 4162US2014221451A1Implants for the treatment of dopamine associated statesUNIV PENNSYLVANIA·Filed 2014·Application pending·0 cites
- 4261US2014147486A1Implants for the treatment of dopamine associated statesUNIV PENNSYLVANIA·Filed 2013·Application pending·0 cites
- 4360US2023000792A1Treatment of 22q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4458US2014163452A1Pharmacokinetics of iontophoretic sumatriptan administrationNUPATHE INC·Filed 2013·Application pending·0 cites
- 4558US2023000793A1Treatment of 22q11.2 deletion syndrome with cannabidiolZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4657US2024307418A1Treatment of sleep apnea with cbdZYNERBA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4756US2014178449A1Methods for treating parkinson's diseaseNUPATHE INC·Filed 2013·Application pending·0 cites
- 4856US2024009210A1Cannabidiol for the Treatment of Refractory SeizuresZYNERBA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4955US9592291B2Methods for iontophoretically treating nausea and migraineNUPATHE INC·Filed 2014·Granted Mar 14, 2017·0 cites·16 claims
- 5055US2016317495A1Pharmacokinetics of iontophoretic sumatriptan administrationTEVA PHARMACEUTICALS INT GMBH·Filed 2016·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Terri Sebree files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →